{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-075100","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.044188+00:00","generated_at":"2026-05-23T18:57:10.201967+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KalVista licenses sebetralstat Japan rights to Kaken; $11M upfront, up to $24M total plus royalties","bullets":["Upfront payment of $11M plus up to $11M regulatory milestone expected in early 2026.","Also eligible for commercial milestones and mid-twenties% royalties on Japan NHI price.","Sebetralstat is an investigational oral on-demand HAE treatment; could be first oral in Japan.","Kaken will leverage regional expertise; KalVista aims for global commercial launches starting 2025.","Orphan Drug Designation received from MHLW; NDA submitted in Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-075100","json":"https://secwatch.observer/filing/0001193125-25-075100.json","markdown":"https://secwatch.observer/filing/0001193125-25-075100.md","text":"https://secwatch.observer/filing/0001193125-25-075100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525075100/0001193125-25-075100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525075100/d829369d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:57:10.201967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}